Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia

Leukemia

Volumn 30, Issue 4, 2016, Pages 947-950

  Khodadoust, M S ^a   Luo, B ^a,b   Medeiros, B C ^a   Johnson, R C ^b   Ewalt, M D ^b   Schalkwyk, A S ^b   Bangs, C D ^b   Cherry, A M ^b   Arai, S ^a   Arber, D A ^b   Zehnder, J L ^a,b   Gotlib, J ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYDROXYUREA; METHOTREXATE; MITOXANTRONE; PONATINIB; PREDNISONE; TACROLIMUS; ANTINEOPLASTIC AGENT; FGFR1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE;

ACUTE LEUKEMIA; ADULT; B LYMPHOCYTE; BONE MARROW BIOPSY; CASE REPORT; CEREBROSPINAL FLUID; CERVICAL LYMPHADENOPATHY; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG THERAPY; DRUG WITHDRAWAL; FLOW CYTOMETRY; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; LETTER; MALE; METAPHASE; MIDDLE AGED; ODYNOPHAGIA; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; TRISMUS; WHOLE BODY RADIATION; ACUTE DISEASE; GENETICS; LEUKEMIA; PATHOLOGY; PROGNOSIS;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; GENE REARRANGEMENT; HUMANS; IMIDAZOLES; LEUKEMIA; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PYRIDAZINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1;

EID: 84933575176     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.136     Document Type: Letter

References (15)

1. Bain BJ, Gilliland DG, Horny H-P, Vardiman JW. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. In: Swerdlow S, Harris NL, Stein H, Jaffe ES, Theile J, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France: 2008; 68-73
2. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010; 41: 461-476
3. Demiroglu A, Steer EJ, Heath C, Taylor K, Bentley M, Allen SL, et al. The t(8; 22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001; 98: 3778-3783
4. Murati A, Arnoulet C, Lafage-Pochitaloff M, Adelaide J, Derre M, Slama B, et al. Dual lympho-myeloproliferative disorder in a patient with t(8; 22) with BCR-FGFR1 gene fusion. Int J Oncol 2005; 26: 1485-1492
5. Haslam K, Langabeer SE, Kelly J, Coen N, O'Connell NM, Conneally E. Allogeneic hematopoietic stem cell transplantation for a BCR-FGFR1 myeloproliferative neoplasm presenting as acute lymphoblastic leukemia. Case Rep Hematol 2012; 2012: 620967
6. Wakim JJ, Tirado CA, Chen W, Collins R. t(8; 22)/BCR-FGFR1 myeloproliferative disorder presenting as B-Acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature. Leuk Res 2011; 35: e151-e153
7. Morishige S, Oku E, Takata Y, Kimura Y, Arakawa F, Seki R, et al. A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation. Acta Haematol 2013; 129: 83-89
8. Dolan M, Cioc A, Cross NC, Neglia JP, Tolar J. Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion. Pediatr Blood Cancer 2012; 59: 194-196
9. Chase A, Bryant C, Score J, Cross NC. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica 2013; 98: 103-106
10. Ren M, Qin H, Ren R, Cowell JK. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia 2013; 27: 32-40
11. Townsend W, Cross NC, Waghorn K, Somana K, Ramsay A, Thomson K, et al. Clinical evidence for a graft-versus-Tumour effect following allogenic HSCT fo t(8; 13) atypical myeloproliferative disorder. Bone Marrow Transplant 2009; 44: 197-199
12. Richebourg S, Theisen O, Plantier I, Parry A, Soenen-Cornu V, Lepelley P, et al. Chronic myeloproliferative disorder with t(8; 22)(p11; q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia. Genes Chromosomes Cancer 2008; 47: 915-918
13. Fioretos T, Panagopoulos I, Lassen C, Swedin A, Billström R, Isaksson M, et al. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8; 22)(p11; q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer 2001; 32: 302-310
14. Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 2007; 110: 3729-3734
15. Chen J, DeAngelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101: 14479-14484